| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Gadolinium-Based Contrast Agents Alone Not Sufficient to Cause Nephrogenic Systemic Fibrosis LEESBURG, Va -- June 30, 2009 -- Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study published in the June issue of the American Journal of Roentgenology. Some research has indicated that NSF is caused by gadolinium-based contrast agents that are commonly used during imaging procedures. Mellena D. Bridges, MD, Mayo Clinic, Jacksonville, Florida, and colleagues examined the records of 61 patients who received high-dose IV gadodiamide for catheter angiography or computed tomography (CT) between January 2002 and December 2005. The cohort was limited to patients who had received a dose of at least 40 mL of gadodiamide during a single imaging session, who underwent at least 1 year of clinical follow-up, and who had moderate to end-stage renal disease. “Our patients had been given high doses, from 2 to 10 times the usual MRI dose,” said Dr. Bridges. “These high doses were used because the patients were undergoing interventional procedures and the procedures were done before there were any reports linking gadolinium to NSF.” “Fortunately, only 1 of these patients, a 58-year-old diabetic man with end-stage kidney disease and significant blood vessel blockages, developed NSF.” “Gadolinium seems to be necessary to trigger NSF, but it doesn’t seem to be enough to cause the disease, even at very high doses,” she concluded. SOURCE: American Roentgen Ray Society
|